ReviewThe Lancet. Infectious diseases2023
Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
Review in The Lancet. Infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of global COVID-19 vaccine PPPs: drivers and barriers to governance alignment.Frontiers in public health · 2025Pooled it
- From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.Vaccines · 2026Article
- Article
- Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases.BMJ medicine · 2026Review
- Africa is an Essential Partner in the Research and Development of an HIV Vaccine.Current HIV research · 2026Review
- Enhancing Diagnostic Infrastructure Through Innovation-Driven Technological Capacity in Healthcare.Healthcare (Basel, Switzerland) · 2025Article
- Enablers, obstacles, value chain and business models for private digital health business on global goods: a collective case study on private entrepreneurs in Uganda digital health space.BMC health services research · 2025Article
- Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections.Vaccines · 2025Review
- Africa's vaccines manufacturing revolution: Lessons from COVID-19, ongoing efforts, and challenges to overcome.Innovations in pharmacy · 2025Article
- Current State and Challenges of Local Production of Vaccines in Nigeria.Public health challenges · 2024Article
- WHO global research priorities for sexually transmitted infections.The Lancet. Global health · 2024Review
- Systematic documentation of the introduction of COVID-19 vaccines in Latin America and the Caribbean.Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Advancing Immunization in Africa: Overcoming Challenges to Achieve the 2030 Global Immunization Targets.Adolescent health, medicine and therapeutics · 2024Review
- 'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.PLOS global public health · 2024Article
- Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine.Pathogens (Basel, Switzerland) · 2023Review
- Leveraging the positives from the pandemic to strengthen infectious disease care in low-income and middle-income countries.The Lancet. Infectious diseases · 2023Article
- Vaccine development against tuberculosis before and after Covid-19.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic heralded unprecedented resource mobilisation and global scientific collaboration to rapidly develop effective vaccines. Regrettably, vaccine distribution has been inequitable, particularly in Africa where manufacturing capacity remains nominal. To address this, several initiatives are underway to develop and manufacture COVID-19 vaccines in Africa. Nevertheless, diminishing demand for COVID-19 vaccines, the cost competitiveness of producing goods locally, intellectual property rights issues, and complex regulatory environments among other challenges can undermine these ventures. We outline how extending COVID-19 vaccine manufacturing in Africa to include diverse products, multiple vaccine platforms, and advanced delivery systems will ensure sustainability. Possible models, including leveraging public-academic-private partnerships to enhance success of vaccine manufacturing capacity in Africa are also discussed. Intensifying research in vaccine discovery on the continent could yield vaccines that further bolster sustainability of local production, ensuring greater pandemic preparedness in resource-constrained environments, and long-term health systems security.
Indexed as
Identifiers
37290473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.